Speedel stays at neutral by Merrill

Speedel Holdings was retained at neutral by Merrill Lynch analyst Erica Whittaker after the company reported a second-quarter loss of CHF 19.7 million, compared to the analyst's estimate of CHF 20.8 million. Speedel also announced that Abbott had declined to take up its development and commercialization option for SPP200, an anti-thrombin drug. Shares of the Basel, Switzerland, pharmaceutical company were down CHF 1.40, or 0.96%, at CHF 144.60 on volume of 9,078 shares versus the three-month running average of 9,078 shares. (Swiss: SPPN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.